Cytiva expands Fast Trak™ process development and validation services facility in India

February 25, 2026

• ~30,000 ft² center will help biopharma shorten development timelines, reduce risk, and scale with confidence
• Supports multiple modalities including mAbs, pDNA/mRNA, recombinant proteins, and viral vectors

Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru, India. The center will help biopharma companies in India and across Asia-Pacific shorten development timelines, reduce manufacturing risk, and scale confidently — as India aims to grow its bioeconomy to USD 300 billion by 2030.

The ~30 000 ft² facility brings together upstream and downstream process development, optimization and scale-up, and validation services under one roof. It also offers immersive training to provide customers with the knowledge and skills to accelerate their molecule-to-market journey.

Cytiva’s Fast Trak facility in Bengaluru, India

Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, says: “India’s scientific strength plays a vital role in global biopharma, and this facility reinforces that momentum. By expanding our capabilities here, we’re giving customers the infrastructure to move from idea to impact with greater speed, reliability, and excellence.”

Manoj Panicker, General Manager, Cytiva South Asia, says: “This facility will enable our customers to innovate faster while maintaining complete control of their processes—improving access to life-saving medicines. This is especially critical for rare diseases, emerging modalities, and the growing biosimilars market, where speed and flexibility are essential.”

Building bioprocessing strength for India and the world

According to Cytiva's 2025 Biopharma Index, 56% of global biopharma executives agree that domestic manufacturing of biologics is set to increase dramatically over the next three years. This is especially apparent in India, where demand for biologics and biosimilars is rising and customers increasingly need localized expertise with global quality standards.

The facility offers robust process development and validation services to meet diverse biopharma needs

Deployed in a GLP-compliant biosafety level 2 (BSL-2) environment, Cytiva’s PD solutions at Fast Trak India are designed for single‑use bioreactor scale up to 200L and can produce toxicity batch material to support preclinical stages. The ISO‑certified validation lab provides specialized testing and documentation services for sterilizing grade filters and single-use system needs.

By offering comprehensive services aligned to sustainability best practices, Cytiva empowers customers to increase yield, improve product quality, reduce manufacturing time and cost, and ensure regulatory compliance. This integrated approach gives biotechs access to infrastructure and expertise that enables faster progress from early development to commercialization in a rapidly evolving biopharma landscape.

Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

---

Media contact:

Darshana Sankararaman
darshana.sankararaman@cytiva.com

About Cytiva

At Cytiva, a Danaher company, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.